CasNo.545445-44-1,3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-one,(545445-44-1) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: ≥98.0%
Payment Terms : T/T,Other

Keywords

545445-44-1 3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-one High purity Apixaban Intemediate

Quick Details

Appearance:White to off-white power
Application:Pharmaceutical Intermediate
PackAge:1kg/bag, 10kg/drum, 25kg/drum (on request)
ProductionCapacity:1|Metric Ton|Month
Storage:Cool, shading, dry and sealed
Transportation:By courier,by air,by sea.

Superiority:

3-MORPHOLIN-4-YL-1-[4-(2-OXWPIPERIDIN-1-YL)PHENYL]-5,6-DIHYDRO-1H-PYRIDIN-2-ONE (545445-44-1)

Information

The product is an Apixaban intemediate.

Quality

Advanced technology

Supper quality

Effective & safety package

Service

Professional and timely afte-sale service(replied within 12h)

COMPANY INFORMATION

Jinan Kangcheng Pharmaceutical Technology Co., Ltd.

Add:Jinan Area,China(Shandong) Pilot Free Trade Zone,China

The company focuses on the development and transfer of pharmaceutical technology. It is a modern enterprise integrating technology development, transfer and sales of APIs, pharmaceutical intermediates, and nutraceutical raw materials.

The company adheres to the principle of integrity and innovation, and provides customers with professional products and advanced technical services.

Details:

3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-one
Product information	English Name：3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-one
	English Alias：5,6-Dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperidinyl) -phenyl]-2(1H)-pyridinone; Apixaban Intermediate
	Chinaese Name：5,6-二氢-3-(4-吗啉基)-1-[4-(2-氧代-1-哌啶基)苯基]-2(1H)-吡啶酮 Apixaban Intermediate
	Chinaese Alias：5,6-二氢-3-（4-吗啉基）-1- [4-（2-氧-1-哌啶基）苯基] -2（1H）-吡啶酮阿哌沙班中间体
	CAS号：545445-44-1
	Formula：C20H25N3O3
	Molecular weight：355.43

	Appearance：White to off-white power
	Assay：98.0%
Use&Pharmacology	This product is an intermediate of Apixaban. Apixaban (ELIQUIS) is an oral selective activation factor X inhibitor, jointly developed by Pfizer and Bristol-Myers Squibb. Eliquis can prevent thrombosis, but the adverse effects of bleeding are lower than that of the old drug warfarin. It is used for thrombosis prevention in patients who have undergone hip or knee replacement surgery. In 2007, Bristol-Myers Squibb and Pfizer formally implemented a global strategic cooperation agreement to jointly develop and sell the anticoagulant product Apixaban; in 2011, it was the first to approve the use of elective hip joints in the 27 EU countries, Iceland and Norway. Prevention of venous thrombosis in adult patients undergoing knee replacement surgery; In January 2013, obtained the import drug license issued by the State Food and Drug Administration of China for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery Event (VTE), and then officially listed in China in April 2013. Apixaban is a new type of oral anticoagulant, a new type of oral factor Xa inhibitor, and a drug used to prevent and treat blood clots. The recommended dose is 2.5 mg, taken orally twice a day, which can effectively prevent venous thromboembolism without increasing the risk of bleeding. There is no need for routine monitoring of coagulation function and no dose adjustment.
Package&Storage	Package：1kg/bag, 10kg/drum, 25kg/drum (on request)
Package&Storage	Storage&Validity：Cool, shading, dry and sealed/2years